193 related articles for article (PubMed ID: 33774697)
1. Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy.
Verver D; Grünhagen DJ; van Akkooi ACJ; Aarts MJB; van den Berkmortel FWPJ; van den Eertwegh AJM; de Groot JWB; Boers-Sonderen MJ; Haanen JBAG; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Tije AJT; Vreugdenhil G; Verhoef C; van der Veldt AAM
Cancer Immunol Immunother; 2021 Nov; 70(11):3123-3135. PubMed ID: 33774697
[TBL] [Abstract][Full Text] [Related]
2. Survival and therapeutic response in patients with melanoma of unknown and known primary: a single-centre retrospective analysis.
Ludwig SV; F Cheng P; Mangana J; Braun R; Dummer R; Koelblinger P
Eur J Dermatol; 2020 Dec; 30(6):699-709. PubMed ID: 33459260
[TBL] [Abstract][Full Text] [Related]
3. Improved survival for stage IV melanoma from an unknown primary site.
Lee CC; Faries MB; Wanek LA; Morton DL
J Clin Oncol; 2009 Jul; 27(21):3489-95. PubMed ID: 19451446
[TBL] [Abstract][Full Text] [Related]
4. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma.
Lee CC; Faries MB; Wanek LA; Morton DL
J Clin Oncol; 2008 Feb; 26(4):535-41. PubMed ID: 18235114
[TBL] [Abstract][Full Text] [Related]
5. Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature.
Utter K; Goldman C; Weiss SA; Shapiro RL; Berman RS; Wilson MA; Pavlick AC; Osman I
Oncology; 2017; 93(4):249-258. PubMed ID: 28746931
[TBL] [Abstract][Full Text] [Related]
6. Melanoma of unknown primary origin: a population-based study in the Netherlands.
de Waal AC; Aben KK; van Rossum MM; Kiemeney LA
Eur J Cancer; 2013 Feb; 49(3):676-83. PubMed ID: 23031553
[TBL] [Abstract][Full Text] [Related]
7. Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies.
Bae JM; Choi YY; Kim DS; Lee JH; Jang HS; Lee JH; Kim H; Oh BH; Roh MR; Nam KA; Chung KY
J Am Acad Dermatol; 2015 Jan; 72(1):59-70. PubMed ID: 25440435
[TBL] [Abstract][Full Text] [Related]
8. Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population-based study.
Verver D; van der Veldt A; van Akkooi A; Verhoef C; Grünhagen DJ; Louwman WJ
Int J Cancer; 2020 Jan; 146(1):26-34. PubMed ID: 30801710
[TBL] [Abstract][Full Text] [Related]
9. Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas.
Egberts F; Bergner I; Krüger S; Haag J; Behrens HM; Hauschild A; Röcken C
Ann Oncol; 2014 Jan; 25(1):246-50. PubMed ID: 24276025
[TBL] [Abstract][Full Text] [Related]
10. Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary.
Tarhini AA; Lee SJ; Tan AC; El Naqa IM; Stephen Hodi F; Butterfield LH; LaFramboise WA; Storkus WJ; Karunamurthy AD; Conejo-Garcia JR; Hwu P; Streicher H; Sondak VK; Kirkwood JM
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35074904
[TBL] [Abstract][Full Text] [Related]
11. Stage IV melanoma of unknown primary: A population-based study in the United States from 1973 to 2014.
Scott JF; Conic RZ; Thompson CL; Gerstenblith MR; Bordeaux JS
J Am Acad Dermatol; 2018 Aug; 79(2):258-265.e4. PubMed ID: 29580859
[TBL] [Abstract][Full Text] [Related]
12. Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort.
Rousset P; Dalle S; Mortier L; Dereure O; Dalac S; Dutriaux C; Leccia MT; Legoupil D; Brunet-Possenti F; De Quatrebarbes J; Grob JJ; Saiag P; Maubec E; Stoebner PE; Granel-Brocard F; Arnault JP; Allayous C; Oriano B; Lebbe C; Montaudié H
J Am Acad Dermatol; 2023 Apr; 88(4):808-815. PubMed ID: 36543626
[TBL] [Abstract][Full Text] [Related]
13. Melanoma of Unknown Primary: Evaluation of the Characteristics, Treatment Strategies, Prognostic Factors in a Monocentric Retrospective Study.
Del Fiore P; Rastrelli M; Dall'Olmo L; Cavallin F; Cappellesso R; Vecchiato A; Buja A; Spina R; Parisi A; Mazzarotto R; Ferrazzi B; Grego A; Rotondi A; Benna C; Tropea S; Russano F; Filoni A; Bassetto F; Tos APD; Alaibac M; Rossi CR; Pigozzo J; Sileni VC; Mocellin S
Front Oncol; 2021; 11():627527. PubMed ID: 33747946
[TBL] [Abstract][Full Text] [Related]
14. Survival after lymphadenectomy of nodal metastases from melanoma of unknown primary site.
Gullestad HP; Ryder T; Goscinski M
J Plast Surg Hand Surg; 2023; 57(1-6):109-114. PubMed ID: 34878354
[TBL] [Abstract][Full Text] [Related]
15. Melanoma patients with an unknown primary tumor site have a better outcome than those with a known primary following therapeutic lymph node dissection for macroscopic (clinically palpable) nodal disease.
van der Ploeg AP; Haydu LE; Spillane AJ; Scolyer RA; Quinn MJ; Saw RP; Shannon KF; Stretch JR; Thompson JF
Ann Surg Oncol; 2014 Sep; 21(9):3108-16. PubMed ID: 24802907
[TBL] [Abstract][Full Text] [Related]
16. Comparative genomic characterization of melanoma of known and unknown primary.
Rassy E; Boussios S; Chebly A; Farra C; Kattan J; Pavlidis N
Clin Transl Oncol; 2021 Nov; 23(11):2302-2308. PubMed ID: 33934271
[TBL] [Abstract][Full Text] [Related]
17. Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site.
Prens SP; van der Ploeg AP; van Akkooi AC; van Montfort CA; van Geel AN; de Wilt JH; Eggermont AM; Verhoef C
Ann Surg Oncol; 2011 Dec; 18(13):3586-92. PubMed ID: 21611857
[TBL] [Abstract][Full Text] [Related]
18. Brain metastases in adult patients with melanoma of unknown primary in the Netherlands (2011-2020).
Padilla CS; Ho VKY; Mooijenkind TWAN; Louwman MWJ; de Vos FYFL; Bekkenk MW; Minnaard WA; Loef C; van Zanten SEMV
J Neurooncol; 2023 May; 163(1):239-248. PubMed ID: 37169949
[TBL] [Abstract][Full Text] [Related]
19. Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study.
Uprety D; Bista A; Chennamadhavuni A; Niroula A; Jafri SIM; Smith A; Arjyal L
Melanoma Res; 2018 Feb; 28(1):56-60. PubMed ID: 29023264
[TBL] [Abstract][Full Text] [Related]
20. Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors.
Waninger JJ; Ma VT; Journey S; Skvarce J; Chopra Z; Tezel A; Bryant AK; Mayo C; Sun Y; Sankar K; Ramnath N; Lao C; Sussman JB; Fecher L; Alva A; Green MD
JAMA Netw Open; 2021 Mar; 4(3):e210980. PubMed ID: 33687443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]